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Abstract:  Epidemiological studies suggest that alcohol consumption increases the risk of developing colorectal cancer.
However, the data are confounded by numerous cosegregating variables.  To cast further light on the relationships
between alcohol intake and colon cancer development, 21-day-old male F344/DuCrj rats were fed 200 ppm 2-amino-
3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) in their diet for 8 weeks and doses of 0, 0.1, 0.3, 1, 3, 10 and 20% of
ethanol in their drinking water ad libitum for 16 weeks thereafter.  The rats were sacrificed after 24 weeks of experiment,
and aberrant crypt foci (ACF), surrogate lesions for colon cancer, were examined under a light microscope at low
magnification.  Ethanol was found not to affect the ACF formation at any dose compared with the initiated-controls.
Furthermore, ethanol did not alter colon epithelial cell proliferation.  These data, obtained by analysis of a colon cancer
surrogate marker lesion, indicate that ethanol lacks promotion activity for MeIQx-initiated rat colon carcinogenesis.
(J Toxicol Pathol 2009; 22: 65–70)
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Introduction
There is abundant epidemiological evidence showing
that excessive and chronic alcohol consumption contribute
to cancer development in organs such as the oral cavity,
pharynx, larynx, esophagus, liver and breast1.  The
epidemiologic data concerning the association between
alcohol consumption and colorectal cancer are not as clear as
those concerning cancers of the upper aerodigestive tract.
Most studies, however, have detected a positive correlation2.
In 1999, a consensus conference of the World Health
Organization on Nutrition and Colorectal Cancer concluded
that chronic alcohol ingestion, even with low daily intake
(one to three drinks or 10 to 40 g per day), results in a 1.5- to
3.5-fold increase in risk of rectal cancer and a lesser increase
in risk of colonic cancer in both sexes3.  This conclusion also
gained support at a meeting on alcohol and cancer at the
International Agency for Research on Cancer4.
Experimental animal studies are critical in clarifying
the role of alcohol in organ carcinogenesis.  It has been
reported that ethanol per se does not have carcinogenic
activity even after lifelong exposure in rodents5.  The
hypothesis is therefore that alcohol may act as a co-
carcinogen or tumor-promoter for colon carcinogenesis1.
However, experimental data on alcohol and colorectal
cancer are controversial and complex, depending on the
experimental design6–8.  In general, it can be concluded that
alcohol stimulates colorectal carcinogenesis primarily
during the preinitiation and initiation phases, as interaction
may occur between ethanol and procarcinogenic metabolism
in these phases2.
Heterocyclic amines (HCAs) are ubiquitously present
in cooked foods and are known to form DNA adducts in
experimental animals and human9.  Recent epidemiological
studies have indicated that increased risk of colorectal cancer
development is associated with high intake of red meat and
HCAs, such as 2-amino-3,8-dimethylimidazo[4,5-f]
quinoxaline (MeIQx)10,11.  MeIQx is strongly mutagenic in
the Ames test12 and is carcinogenic in rodents when fed at
high doses, inducing tumors in the livers, Zymbal glands,
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skin and clitoral glands of rats at a dose of 400 ppm in their
diet13 and in the livers, lungs, and hematopoietic systems of
mice at a dose of 600 ppm14.  It has also been documented
that MeIQx induces aberrant crypt foci (ACFs), surrogate
marker lesions for colon cancers, in rats15 and mice16.
Exposure of humans to HCAs is all but inescapable, and
many people drink alcohol; however, only a limited amount
of data are available concerning the effects of interaction
between HCAs and alcohol with regard to colon
carcinogenesis, especially from in vivo experiments.  In the
present study, we therefore examined the potential for the
ability of ethanol to promote MeIQx-induced colon
carcinogenesis in rats.  For this purpose, we focused on
ACFs in tissue samples from a previous study that
demonstrated dose-dependent promotion of MeIQx-induced
hepatocarcinogenesis by ethanol in male rats17.
Materials and Methods
Chemicals and antibodies
Ethanol (99.5%) was purchased from Wako Pure
Chemical Industries, Ltd. (Osaka, Japan), and MeIQx was
purchased from the Nard Institute (Osaka, Japan).  Mouse
anti-proliferating cell nuclear antigen (PCNA) monoclonal
antibodies were obtained from Dako (Carpinteria, CA,
USA).
Animals
A total of 125 male, 20-day-old, F344/DuCrj rats were
purchased from Charles River Japan (Atsugi, Japan).  Their
housing conditions and treatment were as described
previously17.
Ethics
The experiments were conducted in accordance with
the guidelines for Animal Experiments at Osaka City
University Medical School, which are in line with other
domestic and international guidelines and laws concerning
animal rights.
Experimental design
One hundred and twenty-five, 21-day-old, F344/DuCrj
rats were divided into eleven experimental groups.  The
numbers of rats in the groups were 15 (groups 1 to 7) or 5
(groups 8 to 11) per group.  In groups 1 to 7 and 11, the rats
were fed MF pellet diet mixed with 200 ppm MeIQx
(Oriental Yeast Co., Ltd., Tokyo, Japan), and water was
provided ad libitum for the first 8 weeks; groups 8 to 10 were
fed MF pellet diet without MeIQx.  The animals in groups 10
and 11 were euthanized at experimental week 8.  Thereafter,
the remaining rats received doses of 0 (groups 1 and 8), 0.1
(group 2), 0.3 (group 3), 1 (group 4), 3 (group 5), 10 (group
6) and 20% ethanol (vol/vol; groups 7 and 9) in their
drinking water and MF pellet diet ad libitum for 16 weeks.
During the period of ethanol administration, the drinking
water was changed six times per week.  At experimental
week 24, all rats were euthanized after overnight withdrawal
of food.  At sacrifice, the animals were anesthetized with
diethyl ether, and their colons were quickly removed.  After
evaluation of ACF, two samples of the proximal, middle and
distal colon were cut into strips and routinely processed for
embedding in paraffin.  Sections were stained with
hematoxylin and eosin (H&E) for histopathological and
immunohistochemical examination.  Diagnosis and
classification of tumors and hyperplasias were performed
according to the nomenclature for classification of colon
tumors and preneoplastic lesions in the rat proposed by
IARC18.  The hyperplastic lesions recognized in the present
study were all atypical hyperplasias and did not include a
focal or reactive hyperplasia.
ACF counts
Colons were quickly excised, flushed with saline,
inflated by intraluminal injection of 10% phosphate-buffered
formalin solution, slit open along the longitudinal median
axis from the cecum to anus and fixed flat between two
pieces of filter paper in 10% phosphate-buffered formalin.
After fixation for at least 24 h at 4°C, all colons were stained
with 0.2% methylene blue (in H2O) for 3–5 min and then
examined for ACF by light microscopy at 40× and 100×
magnification using the following criteria for identification:
(1) increased size compared with normal crypts, (2) enlarged
pericryptal zone, (3) slight elevation above the surrounding
mucosa and (4) more frequent occurrence of an elongated
luminal opening.  ACFs were assessed for the number of
aberrant crypts in each focus (1 crypt, 2 crypts, 3 crypts and
≥4 crypts).
Immunohistochemistry for PCNA
Immunoenzymatic staining for PCNA was performed
after sequential treatment with 3% H2O2, exposure to an anti-
PCNA mouse monoclonal antibody at room temperature for
1 hr and then horseradish peroxidase coupled to an inert
polymer backbone (Dako EPOS, Dako Cytomation,
Carpenteria, CA, USA).  The sites of peroxidaase binding
were demonstrated by DAB.  More than 500 epithelial cells
of well-visualized crypts from normal-appearing mucosa
were counted per colonic segment under a light microscope.
PCNA indices were estimated as the numbers of positive
nuclei per 100 epithelial cells (%).  In groups 1 to 7, 6
animals were evaluated.  Immunohistochemical evaluation
of PCNA was performed in a blind manner.
Statistical analysis
Statistical analysis was performed with Statistical
Analysis System (SAS) version 9.1.3 (SAS Institute
Incorporated, Cary, North Carolina, USA).  For the
incidences of colon tumors, hyperplasias and ACFs, the
Fisher’s exact probability test was employed.  For
experiments using single dose levels of MeIQx or ethanol,
the data for each group were first analyzed with the F-test for
homogeneity of variance.  If homogeneous, the data were
analyzed by the Student’s t test, and if not, they were by the
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dose levels of ethanol, the data were initially tested for
homogeneity using Bartlett’s analysis.  For data found to be
homogeneous, Dunnett’s multiple analysis was performed.
If the data were not homogeneous, Steel’s multiple analysis
was conducted.  The significance of differences was
determined based on probability levels of 1% and 5%.  The
data are presented as means or means ± standard deviation
(SD).
Results
Final body weights, food consumption and water intake
At week 8, all rats were in good general condition, and
there were no significant differences among the groups with
regard to food consumption and water intake (data not
shown).  After week 8, food consumption of the rats in
Groups 5, 6 and 7, which were administered a dose of 3, 10
or 20% ethanol, was significantly decreased compared with
the initiated control Group 1 (Table 1).  Furthermore, water
intake of the rats in Groups 6 and 7, which were
administered a doses of 10 and 20% ethanol, was
significantly decreased compared with the initiated control
Group 1.  In Group 4, water intake was significantly
increased compared with the initiated control Group 1, but
there was no dose-dependence.  Therefore, the increased
water intake in Group 4 was not considered to have any
toxicological implications.  One non-initiated rat
administrated 20% ethanol (Group 9) died in experimental
week 11, and emaciation was observed at autopsy.  The final
body weights of rats in Groups 6 and 7 were significantly
reduced compared with Group 1.  In the groups without
MeIQx-treatment (Group 8 and 9), administration of 20%
ethanol also reduced final body weight, food consumption
and water intake (Table 1).
Effects of ethanol on ACF formation
At week 8, ACFs were observed in all MeIQx-treated
rats (Group 11); however, no ACFs were observed in the no-
treatment rats (Group 10; Table 2).  At experimental week
24, the animals treated with MeIQx developed ACFs without
relation to ethanol treatment (Fig. 1A–D).  The incidences
and multiplicities of ACFs in rats administered doses of 0.1
to 10% ethanol (Groups 2 to 6) were not different from those
of the control Group 1 (Table 2).  In the 20% ethanol
treatment group (Group 7), there were no differences in the
incidences of any type of ACF compared to the control group
(Group 1).  There was no difference in ACF multiplicity
between Group 7 and the control group with exception of a
significant decrease in ACFs with 3 crypts.  No statistically
significant differences in formation of ACFs were observed
between the non-treatment (Group 8) and ethanol only
treatment groups (Group 9).
Effects of ethanol on formation of proliferative lesions
In animals administered doses of 0.1, 0.3, 10 and 20%
ethanol after MeIQx treatment, a few hyperplasias and
adenomas were observed in the colon at experimental week
24.  However, there was no relationship between formation
of hyperplastic and neoplastic lesions and ethanol intake
(Table 3).
Evaluation of cell proliferation by 
immunohistochemistry for PCNA
The results of immunohistochemical staining for
PCNA, a marker for cell proliferation, are presented in Table
3.  The PCNA-positive indices for the colon mucosa did not
differ between the ethanol treatment groups at any dose and
the initiated controls.  Ethanol also had no effect on cell
proliferation in the non-MeIQx treatment groups.
Table 1. Body Weight, Food Consumption, Water Intake and Ethanol Intake Data for Rats Treated with MeIQx (8 Weeks) and/or Ethanol (16
Weeks)
Group Treatment No. of rats Final body Average food Average water Average ethanol
(terminal) weight (g) consumption (g/head/day) intake (g/head/day) intake (g/kg B.W./day)
1 MeIQx alone 15 385 ± 18 13.0 ± 0.3 20.0 ± 1.4 0
2M e I Q x   →0.1% EtOH 15 383 ± 20 13.1 ± 0.7 20.7 ± 0.9 0.06 ± 0.00
3M e I Q x   →0.3% EtOH 15 378 ± 21 13.2 ± 0.6 20.4 ± 0.8 0.18 ± 0.01
4M e I Q x   →1% EtOH 15 372 ± 25 12.9 ± 0.3 21.0 ± 0.8* 0.64 ± 0.05
5M e I Q x   →3% EtOH 15 379 ± 21 12.7 ± 0.5* 20.6 ± 0.9 1.83 ± 0.09
6M e I Q x   →10% EtOH 15 364 ± 19* 11.0 ± 0.3** 18.1 ± 0.5** 5.37 ± 0.23
7M e I Q x   →20% EtOH 15 322 ± 15** 8.8 ± 0.2** 15.0 ± 0.2** 9.10 ± 0.50
8 Control 5 375 ± 13 13.2 ± 0.8 19.4 ± 0.4 0
9 20% EtOH 4 309 ± 16## 9.1 ± 1.5## 14.0 ± 0.3## 8.60 ± 0.50
10¶ No treatment 5 276 ± 7 11.7 ± 0.0 19.3 ± 0.1 –
11¶ MeIQx alone 5 254 ± 12§ 11.4 ± 0.1 20.1 ± 1.3 –
Values are represented as means ± SD.
¶ The rats in groups 10 and 11 were sacrificed in experimental week 8 before ethanol administration.
* Significantly different from group 1 (P < 0.05).
** Significantly different from group 1 (P < 0.01).
## Significantly different from group 8 (P < 0.01).
§ Significantly different from group 10 (P < 0.05).68 No Promotion by Ethanol of Rat Colon Carcinogenesis
Table 2. Formation of Aberrant Crypt Foci (ACF) in Rats Treated with MeIQx (8 Weeks) and/or Ethanol (16 Weeks)
1 crypt 2 crypts 3 crypts ≥4 crypts Total
Group Treatment n Incidence Multiplicity Incidence Multiplicity Incidence Multiplicity Incidence Multiplicity Incidence Multiplicity
(%) (No./animal) (%) (No./animal) (%) (No./animal) (%) (No./animal) (%) (No./animal)
1 MeIQx alone 15 80 1.7 ± 1.3 87 2.5 ± 1.5 93 2.3 ± 1.3 87 3.5 ± 2.9 100 9.9 ± 4.7
2M e I Q x
→0.1% EtOH 15 50 1.3 ± 1.6 93 2.3 ± 1.2 79 1.5 ± 1.3 100 4.4 ± 2.1 100 9.5 ± 4.1
3M e I Q x
→0.3% EtOH 15 42 1.0 ± 1.4 79 1.7 ± 1.4 86 1.7 ± 1.2 86 2.1 ± 1.4 100 6.5 ± 2.8
4M e I Q x
→1% EtOH 15 57 1.1 ± 1.3 79 2.5 ± 2.0 100 2.0 ± 1.2 93 3.9 ± 3.1 100 9.5 ± 3.8
5M e I Q x
→3% EtOH 15 50 0.9 ± 1.4 86 2.1 ± 1.3 93 2.1 ± 1.1 100 3.9 ± 2.1 100 9.0 ± 3.1
6M e I Q x
→10% EtOH 15 71 1.2 ± 1.4 71 1.6 ± 1.5 86 1.3 ± 1.0 100 3.1 ± 1.5 100 7.2 ± 3.0
7M e I Q x
→20% EtOH 15 69 1.2 ± 1.2 77 2.2 ± 1.6 54 0.9 ± 1.2* 69 2.5 ± 2.3 100 6.8 ± 2.6
8 Control 5 20 0.2 ± 0.5 40 0.4 ± 0.8 40 0.6 ± 1.3 40 0.4 ± 0.8 80 1.6 ± 2.8
9 20% EtOH 4 0 0 0 0 0 0 50 0.5 ± 0.8 50 0.5 ± 0.8
10¶ N o  T r e a t m e n t 5 0 0 0 00 00 00 0
11¶ MeIQx 200 ppm 5 20 0.2 ± 0.5 80 1.2 ± 0.8# 60 0.6 ± 0.6 60 0.6 ± 0.6 100 # 2.6 ± 0.9#
Multiplicity values are presented as means ± SD.
¶ The rats in groups 10 and 11 were sacrificed in experimental week 8 before ethanol administration.
* Significantly different from group 1 (P < 0.05).
# Significantly different from group 10 (P < 0.05).
Fig. 1. Formation of aberrant crypt foci (ACFs) in the colons of F344 rats administered ethanol for 16 weeks after MeIQx initiation for 8 weeks.
A-D show typical ACFs consisting of 1 Crypt (A), 2 Crypts (B), 3 Crypts (C) and 4 Crypts or more (D). The samples are stained with
0.2% methylene blue stain. The original magnification is 100×.
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Discussion
In past epidemiological studies, it has been proposed
that almost 90% of large intestinal cancers might be caused
by dietary factors19.  Many researchers have pointed to
relationships between dietary habits and colon cancer.
HCAs and ethanol itself could be direct risk factors for
human colon cancer, with other factors (fruits, vegetables,
fiber and fecal weight) implicated as modulating their
influences2,20,21.  However, in the present study, we could not
find any evidence that ethanol promotes MeIQx-induced
ACF formation, although it has previousely been found to
promote the formation of hepatocellular adenomas and/or
carcinomas at doses of 3% or more via induction of
cytochrome P450 2E1 (CYP 2E1)17.  Previous studies of
colorectal cancer using carcinogen-treated (azoxymethane or
1,2-dimethylhydrazine) rodent models have also suggested
that ethanol does not promote colon carcinogenesis7,8.
On the other hand, ethanol may be considered a co-
carcinogen, and the mechanisms of colorectal
carcinogenesis stimulation of ethanol could well be related
to metabolism of procarcinogens2.  To clarify the effects of
interaction between HCAs and ethanol in colon
carcinogenesis, further studies after treatment with potent
colon carcinogenic HCAs, PhiP (2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine) or MeIQ (2-amino-3-
methylimidazo[4,5-f]quinoline), are needed.
In the present study, ACF formation seemed to be
affected in the 20% ethanol treatment group (Group 7)
compared with the MeIQx-alone group (Group 1).  The
multiplicity of 3 crypt ACFs in Group 7 was significantly
decreased, although other findings, such as the incidences of
ACF, tumor formation and cell proliferation, were not
affected.  A similar tendency without statistical significance
was observed for formation of ACFs in the ethanol only
treatment group (Group 9) compared with the non-treatment
group (Group 8).  Several studies have revealed that food
restriction inhibits development of ACFs and colon
tumors22,23.  In this context, it is interesting that food
consumption and final body weight were significantly
decreased in the 20% ethanol treatment groups (Group 7 and
9).  These data suggest that the cause of decreased ACF
formation was body weight loss due to decreased food
intake, rather than the ethanol itself.  Indeed, it remains a
possibility that body weight loss nullified any promotion
effects of ethanol on ACF formation.  To clarify whether
calorie restriction affects the effects of ethanol on ACF
formation, further studies with an isocaloric diet are needed.
In conclusion, the present analysis of a surrogate maker
for colon cancer indicates that ethanol has no promotional
effect on MeIQx-initiated rat colon carcinogenesis, although
it does promote rat hepatocarcinogenesis17.
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